Effentora 100 mg; 200 mg; 400 mg; 600 mg; 800 mg Effervescent buccal tablets.
PDF Leaflet Revision Date: 18 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of breakthrough pain in adults with cancer on maintenance opioid therapy.
Dosage (summary)
Initial dose: 100 mcg, titrate as needed; max 800 mcg.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to risks of respiratory depression in the fetus/infant.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Benzodiazepines
- Alcohol
Contraindications
- Hypersensitivity to fentanyl
- Severe respiratory depression
- Patients without maintenance opioid therapy
- Breastfeeding
Common side effects
- Respiratory depression
- Nausea
- Constipation
- Dizziness
Counselling Points
- Do not use with other fentanyl products.
- Store out of reach of children.
- Monitor for signs of respiratory depression.
Serious warnings
- Risk of respiratory depression
- Potential for abuse and dependence
- Accidental exposure can be fatal
Important Disclaimer
The Effentora 100 mg; 200 mg; 400 mg; 600 mg; 800 mg Effervescent buccal tablets. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
